1) What are the unique features of GTP Bioways?
GTP Bioways, a French CDMO with more than 20 years’ experience, provides one-stop-shop services to biopharma companies. From late-stage discovery through preclinical and clinical trials to market readiness, we provide seamless support across the entire development spectrum. Our services include process and analytical development, cGMP manufacturing and aseptic filling. Our distinct advantage lies in our expertise in both mammalian and microbial expression systems, enabling us to manufacture a wide range of large molecules, including proteins, monoclonal antibodies and bioconjugates with highly potent payloads. We also take pride in our integrated fill & finish services for both small and large molecules. At the core of our operations are our customer-centric values: empathy, integrity, and transparency. Our commitment ensures that our clients achieve their development goals effectively.
2) As a CDMO specialized in process development and manufacturing of antibodies, proteins, bioconjugates and nanodrugs, why have you decided to focus on the Medicon Valley region?
The Medicon Valley region is a strategic focus for GTP Bioways due to its prominence as a major biopharmaceutical hub. Denmark and Sweden are renowned for their robust biopharmaceutical ecosystems, featuring cutting-edge research institutions, and a dynamic network of innovative companies. At GTP Bioways, we recognize the unique opportunities presented by this vibrant ecosystem, and we believe that our expertise and capabilities make us the ideal CDMO to support the most advanced and complex biopharmaceutical projects. Being part of MVA will allow us to gain a deeper understanding of the unique needs and priorities of the local biotech environment, ensuring that our services are precisely tailored to meet these demands.
3) How do you expect to benefit from being a member of Medicon Valley Alliance?
Joining the Medicon Valley Alliance (MVA) presents an invaluable opportunity for GTP Bioways to expand its footprint in Scandinavia. MVA provides a unique platform for networking, collaboration, and accessing new opportunities within one of the world’s leading biopharmaceutical hubs. By leveraging MVA’s resources and community, we aim to enhance GTP Bioways’ visibility across the Nordic region. This membership will enable us to forge strong relationships with key stakeholders, including industry leaders, research institutions, and innovative companies. Through these connections, we can share valuable industry insights, and collectively address common challenges and opportunities in the biotech and biopharma sectors. This will help us deliver greater value to our future customers and contribute meaningfully to the success of the biopharmaceutical sector in Denmark and Sweden.